Previous 10 | Next 10 |
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Hi...
Management Team to be Joined by Leading Cancer Researcher, Dr. Yair Levy, Director of Hematologic Malignancies at the Baylor University Medical Center, and Member of the REGAL Steering Committee NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc . (NASDA...
Mohammed Haneefa Nizamudeen/iStock via Getty Images Cantor Fitzgerald has initiated the coverage of SELLAS Life Sciences ([[SLS]] +8.3%) with an overweight rating as the firm cites a compelling risk-reward profile ahead of the company’s interim data for its lead candidate galinpepimut-...
Chembio Diagnostics (CEMI) +93% on receiving $28.3M purchase order from Bio-Manguinhos for DPP SARS-CoV-2. Antigen Tests in BrazilLexaria Bioscience (LEXX) +42% as DehydraTECH significantly enhances delivery of Colchicine in study VIRAL-A20-3.PainReform (PRFX) +27%.Xtant Medica...
Gainers: Alterity Therapeutics (ATHE) +103%, TRxADE HEALTH (MEDS) +62%, Pulse Biosciences (PLSE) +22%, Spero Therapeutics (SPRO) +12%, Kintara Therapeutics (KTRA) +6%.Losers: Citius Pharmaceuticals (CTXR) -21%, Aligos Therapeutics (A...
Mohammed Haneefa Nizamudeen/iStock via Getty Images Updated phase 1/2 data on SELLAS Life Sciences Group's ([[SLS]] -2.7%) lead asset, galinpepimut-S ((GPS)), indicates that the candidate is inducing an immune response in patients with ovarian cancer. Results from 11 patients who receive...
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS Induced WT1-Specific Immune Responses with a Substantial Increase in Antigen-Reactive T-Lymphocytes Averaging +242% for CD8+ and ...
Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of Care is Approximately 28 weeks New and Updated Clinical and Translational ...
NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that...
At the conclusion of the 2021 Russell indexes annual reconstitution, following notable healthcare stocks will join the Russell Microcap Index, effective June 28 after the U.S. market opens.Asensus Surgical (ASXC), Organovo Holdings (ONVO), Senseonics Holdings (SENS), Clovis Onc...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...